New Vic grants support bioinformatics projects
21 February, 2006 by Ruth BeranBiotechnology, genomics and molecular modelling will be boosted with grants from the Victorian Partnership for Advanced Computing (VPAC) with AUD$348,000 in funding for its round eight e-Research grants program.
WA premier promises investment in biotech
17 February, 2006 by Ruth BeranThe Western Australian government is committed to developing the state's biotechnology sector, according to new premier Alan Carpenter, who this week announced AUD$4.5 million in seed funding for a new biotech research facility as well as medical grants totalling $5 million.
Mimotopes signs peptide deal with Invitrogen
15 February, 2006 by Ruth BeranPharmAust's (ASX:PAA) wholly owned subsidiary Mimotopes has signed a three-year contract with California-based Invitrogen to exclusively supply research-grade peptides to the global biotech group's customer base.
Diabetes gene database launched in WA
14 February, 2006 by Claire DobleIn five years' time, Australian researchers aim to know what causes both type 1 and type 2 diabetes, with the help of a new national genetic database that has been set up to collect and study DNA from 3000 Australian families with diabetic children.
Canberra summit to explore Australia's genetic research prospects
23 January, 2006 by Ruth BeranFederal and state MPs are to get an insight into Australian genetic and genomic research capabilities and opportunities, at a national forum to be held in Canberra in February.
Innovation Dynamics earns financial services licence
12 January, 2006 by Staff WritersConsulting firm Innovation Dynamics has added a new string to its bow, after being granted an Australian Financial Services licence by ASIC.
Peter Mac, NICTA team up for cancer software project
21 December, 2005 by Graeme O'NeillAustralia's largest cancer research agency, Melbourne's Peter MacCallum Cancer Centre, is linking up with the National Information and Communications Technology Agency (NICTA) to develop adaptive software to sift huge datasets from microarray chips for patterns of gene activity distinctive to different cancers.
Not a gene out of place
05 December, 2005 by Graeme O'NeillGraeme O'Neill reports back from the recent CSIRO Horizons in Livestock Science conference at the Gold Coast, which addressed the progress, challenges and problems associated with redesigning livestock.
Start-up Haplomics to muscle in on gene-testing market
01 December, 2005 by Graeme O'NeillMelbourne gene-testing company Genetic Technologies (ASX:GTG), currently engaged in a protracted court case with giant US rival Applera over licensing and royalties for GTG's controversial non-coding DNA patents, has a potential rival in its own backyard.
The primordial structure of proteins
01 December, 2005 by Graeme O'NeillIs the tendency to misfold and form aggregates of fibrils and gels the true nature of proteins? Graeme O'Neill reports.
Benitec tells AGM of better times ahead
30 November, 2005 by Helen Schuller"Seeing you all here means the company has survived," the chairman of RNAi specialist Benitec (ASX:BLT) Ray Whitten, told shareholders at today's AGM in Sydney.
Farmacule grows proteins in tobacco
22 November, 2005 by Graeme O'NeillBrisbane agbiotech Farmacule BioIndustries has taken a step towards the era of molecular 'pharming' by producing vitronectin, a high-value human protein used in medical research, in genetically modified tobacco plants.
The great divide: therapeutic cloning
22 November, 2005 by Ruth BeranShould Australia lift its ban on therapeutic cloning? Few topics in Australian science have generated such strong opinions. Ruth Beran reports.
Australian biotech hears the tiger's roar
21 November, 2005 by David BinningDavid Binning finds a wealth of opportunities for Australian integration with other Asian biotech industries.
Good press drove October biotech enthusiasm: Intersuisse
18 November, 2005 by Helen SchullerBiotech shares bucked the trend during the month of October - the Intersuisse biotechnology index gained 6.6 per cent in contrast to the All Ordinaries and the Nasdaq Biotech Index, which fell by 3.9 per cent and 3.8 per cent respectively.
